Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
TipRanksApr 9 18:30
Needham: Reiterated the Recursion Pharmaceuticals (RXRX.US) rating, adjusted from buy to buy rating, target price $17.00.
Zhitong FinanceApr 9 18:26
Recursion Pharmaceuticals Analyst Ratings
BenzingaApr 9 18:18
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
BenzingaApr 9 18:20
Recursion Pharmaceuticals Analyst Ratings
BenzingaMar 4 19:30
Keybanc Maintains Overweight on Recursion Pharmaceuticals, Raises Price Target to $16
BenzingaMar 4 19:32
Analysts Have Conflicting Sentiments on These Healthcare Companies: Beam Therapeutics (BEAM), ACADIA Pharmaceuticals (ACAD) and Recursion Pharmaceuticals (RXRX)
TipRanksFeb 28 19:00
Needham Maintains Buy on Recursion Pharmaceuticals, Raises Price Target to $17
BenzingaFeb 28 18:44
Recursion Pharmaceuticals Analyst Ratings
BenzingaFeb 28 18:43
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Arcutis Biotherapeutics (ARQT)
TipRanksFeb 28 09:10
Recursion Pharmaceuticals Analyst Ratings
BenzingaJan 27 00:33
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $15 Price Target
BenzingaJan 17 19:18
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $15 Price Target
BenzingaJan 16 20:15
Recursion Pharmaceuticals Analyst Ratings
BenzingaJan 16 20:14
Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX), Edgewise Therapeutics (EWTX) and Eledon Pharmaceuticals (ELDN)
TipRanksNov 14, 2023 15:30
JP Morgan Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $10
BenzingaNov 14, 2023 00:03
Recursion Pharmaceuticals Analyst Ratings
BenzingaNov 14, 2023 00:02
Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating
MT NewswiresNov 10, 2023 21:18
Needham Maintains Buy on Recursion Pharmaceuticals, Lowers Price Target to $15
BenzingaNov 10, 2023 06:56
Recursion Pharmaceuticals Analyst Ratings
BenzingaNov 10, 2023 06:54
No Data
No Data